D.E. Shaw & Co
LKFT

D.E. Shaw & Co’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

D.E. Shaw & Co’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-9,200
Closed -$507K – 5674
2021
Q4 		$507K Hold
9,200
– – ﹤0.01% 4394
2021
Q3 		$484K Hold
9,200
– – ﹤0.01% 4099
2021
Q2 		$634K Buy
+9,200
New +$702K ﹤0.01% 3900

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co's LKFT Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 22% in Q1 2026, selling an estimated $1.96M and leaving 215,718 shares worth $6.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1983.

D.E. Shaw & Co first reported a position in LKFT in Q3 2018 and has held it in 26 quarters since. The position peaked at $8.99M in Q4 2025. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • D.E. Shaw & Co held 215,718 shares of Lakefront Biotherapeutics American Depositary Shares worth $6.47M as of Q1 2026.
  • D.E. Shaw & Co sold 59,281 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $1.96M.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1983 holding.
  • D.E. Shaw & Co first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2018 and has held it in 26 quarters since.
  • D.E. Shaw & Co's Lakefront Biotherapeutics American Depositary Shares position peaked at $8.99M in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.